Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of October 2016. The registrant is a foreign private issuer based in Ness Ziona, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is a corporate announcement regarding the exercise of tradable options rather than a financial results report.
Material Changes and Corporate Actions
- Option Exercise Period: Series 3 tradable options (ISIN: IL0011271827), traded exclusively on the Tel Aviv Stock Exchange (TASE), are exercisable until November 6, 2016.
- Last Trading Day: The final day to trade Series 3 options on TASE is November 1, 2016.
- Exercise Price: The price is NIS 1.80 per option, equivalent to approximately $0.47 USD based on the October 9, 2016 exchange rate (3.794 NIS = $1.00).
- Expiration: Unexercised Series 3 options will expire on November 6, 2016, with no residual rights granted to holders.
- Listing Status: Series 3 options are not listed on The NASDAQ Capital Market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed is the expiration of Series 3 options if not exercised by the specified deadline, resulting in the loss of all rights associated with those instruments.
Investor Verification Checklist
- Verify the current status of Series 3 options on the Tel Aviv Stock Exchange (Ticker: BVXV.W3).
- Confirm the exact expiration date (November 6, 2016) and last trading day (November 1, 2016) for Series 3 options.
- Check the prevailing exchange rate between NIS and USD to calculate the current dollar value of the NIS 1.80 exercise price.
- Confirm that Series 3 options are not available for trading on U.S. exchanges (NASDAQ).